Breaking Biotech

045 - Gilead PrEP Revenue in JEOPARDY!


Listen Later

Hey everybody, today I talk about the upcoming advisory committee meeting, which will lead to a recommendation (or not) for the approval of Descovy for pre-exposure prophylaxis (PrEP) in high-risk individuals. I also go through the latest ICER reports on AIMT and AMRN. I mention a short-term trade idea but remember to do your own due diligence and do not consider this investment advice. Thanks for watching! www.breakingbiotech.com Support Breaking Biotech by donating to the tip jar: https://tips.pinecast.com/jar/breaking-biotech
...more
View all episodesView all episodes
Download on the App Store

Breaking BiotechBy Matthew Lepoire

  • 4.9
  • 4.9
  • 4.9
  • 4.9
  • 4.9

4.9

24 ratings


More shows like Breaking Biotech

View all
Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

Biotech Hangout

19 Listeners